Expand / Collapse search
Watch TV
☰

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions.  Legal Statement.

This material may not be published, broadcast, rewritten, or redistributed. ©2026 FOX News Network, LLC. All rights reserved. FAQ - New Privacy Policy

phreesia - PHR

PHR

Close Chg Chg %
8.37 0.84 9.98%

Closed Market

9.20

+0.84 (9.98%)

Volume: 3.31M

Last Updated:

Apr 6, 2026, 4:00 PM EDT

Trade Now

Company Overview: phreesia - PHR

PHR Key Data

Open

$8.56

 Day Range

8.37 - 9.20

52 Week Range

7.77 - 32.76

 Market Cap

$508.59M

Shares Outstanding

60.76M

 Public Float

49.35M

Beta

0.86

 Rev. Per Employee

N/A

P/E Ratio

223.20

 EPS

$0.04

Yield

0.00%

 Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

2.77M

  

PHR Performance

1 Week
 
 9.32%
 
1 Month
 
 -24.07%
 
3 Months
 
 -46.89%
 
1 Year
 
 -62.36%
 
5 Years
 
 -82.70%
 

PHR Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 20
Full Ratings ➔

About phreesia - PHR

Phreesia, Inc. engages in the provision of patient check-in solutions for medical practices. The firm offers appointments, clinical support, integration, registration, patient activation, analytics and reports, revenue cycle, patient surveys, and privacy and security products. Its solutions include health systems, multi-specialty, and federally qualified health centers (FQHCs). The company was founded by Chaim Indig and Evan Roberts in January 2005 and is headquartered in Wilmington, DE.

PHR At a Glance

Phreesia, Inc.
1521 Concord Pike
Wilmington, Delaware 19803
Phone 1-888-654-7473 Revenue 480.59M
Industry Packaged Software Net Income 2.31M
Sector Technology Services 2026 Sales Growth 14.477%
Fiscal Year-end 01 / 2027 Employees 1,789
View SEC Filings

PHR Valuation

P/E Current 223.20
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) 358.133
Price to Sales Ratio 1.718
Price to Book Ratio 2.416
Price to Cash Flow Ratio 10.92
Enterprise Value to EBITDA 24.672
Enterprise Value to Sales 1.778
Total Debt to Enterprise Value 0.12

PHR Efficiency

Revenue/Employee 268,636.669
Income Per Employee 1,288.988
Receivables Turnover 3.108
Total Asset Turnover 0.913

PHR Liquidity

Current Ratio 1.525
Quick Ratio 1.525
Cash Ratio 0.403

PHR Profitability

Gross Margin 61.267
Operating Margin 0.543
Pretax Margin -1.86
Net Margin 0.48
Return on Assets 0.438
Return on Equity 0.766
Return on Total Capital 0.525
Return on Invested Capital 0.655

PHR Capital Structure

Total Debt to Total Equity 30.382
Total Debt to Total Capital 23.302
Total Debt to Total Assets 15.434
Long-Term Debt to Equity 27.646
Long-Term Debt to Total Capital 21.204
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Phreesia - PHR

Collapse All in section
All values USD millions. 2023 2024 2025 2026 5-year trend
Sales/Revenue
280.91M 356.30M 419.81M 480.59M
Sales Growth
+31.74% +26.84% +17.83% +14.48%
Cost of Goods Sold (COGS) incl D&A
138.03M 154.55M 164.63M 186.15M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
28.77M 30.54M 29.70M 32.02M
Depreciation
19.76M 17.58M 14.18M 12.97M
Amortization of Intangibles
7.32M 11.90M 13.70M 18.48M
COGS Growth
+30.34% +11.97% +6.52% +13.07%
Gross Income
142.88M 201.75M 255.18M 294.44M
Gross Income Growth
+33.12% +41.20% +26.49% +15.39%
Gross Profit Margin
+50.86% +56.62% +60.78% +61.27%
2023 2024 2025 2026 5-year trend
SG&A Expense
319.43M 335.12M 310.17M 291.83M
Research & Development
91.24M 112.35M 117.36M 121.48M
Other SG&A
228.18M 222.77M 192.81M 170.35M
SGA Growth
+43.13% +4.91% -7.44% -5.91%
Other Operating Expense
- - - -
-
Unusual Expense
- 4.22M 761.00K 9.51M
EBIT after Unusual Expense
(176.55M) (137.60M) (55.75M) (6.90M)
Non Operating Income/Expense
2.30M 4.11M 2.29M 4.91M
Non-Operating Interest Income
2.48M 4.07M 2.68M 2.17M
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
1.41M 1.85M 2.35M 6.95M
Interest Expense Growth
+21.32% +31.40% +26.59% +196.25%
Gross Interest Expense
1.41M 1.85M 2.35M 6.95M
Interest Capitalized
- - - -
-
Pretax Income
(175.66M) (135.34M) (55.81M) (8.94M)
Pretax Income Growth
-48.89% +22.95% +58.76% +83.98%
Pretax Margin
-62.53% -37.99% -13.29% -1.86%
Income Tax
483.00K 1.54M 2.72M (11.25M)
Income Tax - Current - Domestic
49.00K 76.00K 102.00K 356.00K
Income Tax - Current - Foreign
- 1.24M 2.40M 1.67M
Income Tax - Deferred - Domestic
109.00K 38.00K 214.00K (11.68M)
Income Tax - Deferred - Foreign
- 325.00K 190.00K (1.59M)
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
(176.15M) (136.88M) (58.53M) 2.31M
Minority Interest Expense
- - - -
-
Net Income
(176.15M) (136.88M) (58.53M) 2.31M
Net Income Growth
-49.07% +22.29% +57.24% +103.94%
Net Margin Growth
-62.71% -38.42% -13.94% +0.48%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
(176.15M) (136.88M) (58.53M) 2.31M
Preferred Dividends
- - - -
-
Net Income Available to Common
(176.15M) (136.88M) (58.53M) 2.31M
EPS (Basic)
-3.359 -2.5088 -1.0163 0.0386
EPS (Basic) Growth
-41.82% +25.31% +59.49% +103.80%
Basic Shares Outstanding
52.44M 54.56M 57.59M 59.74M
EPS (Diluted)
-3.359 -2.5088 -1.0163 0.0375
EPS (Diluted) Growth
-41.82% +25.31% +59.49% +103.69%
Diluted Shares Outstanding
52.44M 54.56M 57.59M 61.49M
EBITDA
(147.78M) (102.83M) (25.29M) 34.63M
EBITDA Growth
-61.83% +30.42% +75.41% +236.95%
EBITDA Margin
-52.61% -28.86% -6.02% +7.21%

Snapshot

Average Recommendation OVERWEIGHT Average Target Price 17.444
Number of Ratings 20 Current Quarters Estimate 0.018
FY Report Date 04 / 2026 Current Year's Estimate 0.322
Last Quarter’s Earnings 0.02 Median PE on CY Estimate N/A
Year Ago Earnings 0.04 Next Fiscal Year Estimate 0.587
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 13 13 13 11
Mean Estimate 0.02 0.04 0.32 0.59
High Estimates 0.09 0.11 0.60 1.19
Low Estimate -0.05 -0.03 -0.13 0.05
Coefficient of Variance 240.59 109.15 61.80 48.70

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 13 13 17
OVERWEIGHT 2 1 3
HOLD 5 5 0
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Overweight Overweight Buy

Insider Actions for Phreesia - PHR

Date Name Shares Transaction Value
Apr 18, 2025 Balaji Gandhi Chief Financial Officer 107,547 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $23.81 per share 2,560,694.07
Apr 18, 2025 Allison C. Hoffman General Counsel & Secretary 137,921 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $23.81 per share 3,283,899.01
Apr 18, 2025 Chaim Indig Chief Executive Officer; Director 1,254,574 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $23.81 per share 29,871,406.94
Apr 18, 2025 Evan Roberts Chief Operating Officer 774,807 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $23.81 per share 18,448,154.67
Apr 18, 2025 Amy Beth VanDuyn SVP, Human Resources 129,820 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $23.81 per share 3,091,014.20
Apr 18, 2025 David Linetsky SVP, Life Sciences 219,727 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $23.81 per share 5,231,699.87
Apr 18, 2025 David Linetsky SVP, Life Sciences 217,239 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $23.66 per share 5,139,874.74
Apr 18, 2025 Yvonne Hui Principal Accounting Officer 25,333 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $24.04 per share 609,005.32
Apr 18, 2025 Yvonne Hui Principal Accounting Officer 24,915 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $23.66 per share 589,488.90
Apr 9, 2025 David Linetsky SVP, Life Sciences 9,260 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Apr 9, 2025 David Linetsky SVP, Life Sciences N/A Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00

Phreesia in the News